BioNano Genomics Inc vs Carparts.Com Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Carparts.Com Inc trades at $6.37 (market cap $51.67M). The key difference: Carparts.Com Inc is far larger — about 3.8× BioNano Genomics Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PRTS | |
|---|---|---|
Market Cap | $13.66M | $51.67M |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $11.40 |
52-Week Low | $1.06 | $3.88 |
Enterprise Value | $16.26M | $66.64M |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
PRTS trades at $6.35, up 0.47% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings that beat expectations, with a net loss of -$0.43 per share versus -$0.85 expected. However, fundamentals show declining revenue from $676M in 2023 to $548M in 2025 and negative net income margins. A reverse stock split was executed on May 26, 2026, to maintain Nasdaq compliance.
The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but persistent losses and negative cash flow from operations pose significant risks. Investment opportunity hinges on operational turnaround and proprietary data leverage, while high volatility and competitive pressures require caution.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →